These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 29906252)

  • 1. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.
    Cho J; Kim HS; Ku BM; Choi YL; Cristescu R; Han J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    J Clin Oncol; 2019 Aug; 37(24):2162-2170. PubMed ID: 29906252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
    Rajan A; Carter CA; Berman A; Cao L; Kelly RJ; Thomas A; Khozin S; Chavez AL; Bergagnini I; Scepura B; Szabo E; Lee MJ; Trepel JB; Browne SK; Rosen LB; Yu Y; Steinberg SM; Chen HX; Riely GJ; Giaccone G
    Lancet Oncol; 2014 Feb; 15(2):191-200. PubMed ID: 24439931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.
    Giaccone G; Kim C; Thompson J; McGuire C; Kallakury B; Chahine JJ; Manning M; Mogg R; Blumenschein WM; Tan MT; Subramaniam DS; Liu SV; Kaplan IM; McCutcheon JN
    Lancet Oncol; 2018 Mar; 19(3):347-355. PubMed ID: 29395863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
    Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
    Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
    Rajan A; Heery CR; Thomas A; Mammen AL; Perry S; O'Sullivan Coyne G; Guha U; Berman A; Szabo E; Madan RA; Ballester LY; Pittaluga S; Donahue RN; Tsai YT; Lepone LM; Chin K; Ginty F; Sood A; Hewitt SM; Schlom J; Hassan R; Gulley JL
    J Immunother Cancer; 2019 Oct; 7(1):269. PubMed ID: 31639039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
    Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
    J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA.
    Khan MK; Nasti TH; Qian JY; Kleber TJ; Switchenko JM; Kaufman JL; Nooka AJ; Dhodapkar MV; Buchwald ZS; Obiekwe D; Lonial S; Ahmed R
    Lancet Haematol; 2024 Jul; 11(7):e510-e520. PubMed ID: 38797190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Disis ML; Taylor MH; Kelly K; Beck JT; Gordon M; Moore KM; Patel MR; Chaves J; Park H; Mita AC; Hamilton EP; Annunziata CM; Grote HJ; von Heydebreck A; Grewal J; Chand V; Gulley JL
    JAMA Oncol; 2019 Mar; 5(3):393-401. PubMed ID: 30676622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
    Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
    J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
    Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
    BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
    Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
    Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience.
    Bluthgen MV; Boutros C; Fayard F; Remon J; Planchard D; Besse B
    Lung Cancer; 2016 Sep; 99():111-6. PubMed ID: 27565923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial.
    Conforti F; Zucali PA; Pala L; Catania C; Bagnardi V; Sala I; Della Vigna P; Perrino M; Zagami P; Corti C; Stucchi S; Barberis M; Guerini-Rocco E; Di Venosa B; De Vincenzo F; Cordua N; Santoro A; Giaccone G; De Pas TM
    Lancet Oncol; 2022 Oct; 23(10):1287-1296. PubMed ID: 36096156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
    Plimack ER; Bellmunt J; Gupta S; Berger R; Chow LQ; Juco J; Lunceford J; Saraf S; Perini RF; O'Donnell PH
    Lancet Oncol; 2017 Feb; 18(2):212-220. PubMed ID: 28081914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma.
    Hyun JW; Kim GS; Kim SH; Cho JY; Kim HJ; Lee GK; Kim HJ; Kwon SU
    Clin Lung Cancer; 2020 Mar; 21(2):e74-e77. PubMed ID: 31718909
    [No Abstract]   [Full Text] [Related]  

  • 16. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas.
    Okuma Y; Nomura S; Sakakibara-Konishi J; Tsukita Y; Murakami S; Hosomi Y; Tambo Y; Kogure Y; Yoshioka H; Tamiya M; Ninomiya K; Iwama E
    Clin Lung Cancer; 2024 Jun; 25(4):389-394. PubMed ID: 38413246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis.
    Remon J; Villacampa G; Facchinetti F; Di Maio M; Marcuse F; Tiseo M; Hochstenbag M; Hendriks LEL; Besse B
    Eur J Cancer; 2023 Feb; 180():117-124. PubMed ID: 36592506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
    Bellmunt J; de Wit R; Vaughn DJ; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Poehlein CH; Perini RF; Bajorin DF;
    N Engl J Med; 2017 Mar; 376(11):1015-1026. PubMed ID: 28212060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
    Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.